Back to news

United Therapeutics Corporation Announces First Transplant in EXTEND Clinical Trial of UThymoKidney™ in Patients with End-Stage Renal Disease

Business Wire•20/11/2026•07:00 ET
0

Key Highlights

  • ➤First UThymoKidney transplant performed in EXTEND trial at NYU Langone Health
  • ➤EXTEND is United Therapeutics’ second clinical trial in its xeno-organ program
  • ➤First six transplants require 12-week spacing before independent safety review
  • ➤United Therapeutics plans FDA review of initial six-transplant data before expanding study
  • ➤UThymoKidney uses single-gene-edited porcine organ with thymic tissue to reduce rejection

Expert Statements

Jayme Locke, M.D., Ph.D., Chief Medical Officer, Xenotransplantation at United Therapeutics

“Today marks an exciting moment for United Therapeutics and for the field of xenotransplantation. EXTEND is the second clinical trial in our xeno-organ manufacturing program, and it reflects years of investment in the science, facilities, and regulatory groundwork needed to bring this technology from possibility to clinical reality.”

Leigh Peterson, Ph.D., Executive Vice President, Product Development & Xenotransplantation at United Therapeutics

“We are demonstrating that an investigational manufactured organ program can move methodically from the laboratory to patients, always with patient safety first. We are deeply grateful to the participant, their family, and the NYU Langone team.”

Robert Montgomery, M.D., D.Phil., H. Leon Pachter, M.D., Professor of Surgery; Chair of the Department of Surgery at NYU Grossman School of Medicine; and Director of the NYU Langone Transplant Institute

“Every day, people with kidney failure die waiting for an organ that never comes. The need for new sources of organs is urgent. UThymoKidney is designed with the intention to help a recipient’s immune system accept the organ and reduce the risk of organ rejection. The EXTEND study provides a carefully designed, scientifically rigorous way to determine whether another approach to xenotransplantation can deliver real benefit to patients who have few other options.”

United Therapeutics Corporation Announces First Transplant in EXTEND Clinical Trial of UThymoKidney™ in Patients with End-Stage Renal Disease

The EXTEND study is the first clinical trial to evaluate xenotransplantation of a porcine thymokidney in a patient with end-stage renal disease (ESRD)

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in